20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 02 Aug 2018 Planned End Date changed from 23 Feb 2020 to 15 Nov 2019.
    • 02 Aug 2018 Planned primary completion date changed from 6 Jun 2019 to 4 Apr 2019.
    • 28 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top